RATS IMMUNIZED WITH CHOLINERGIC SYNAPTOSOMES - A MODEL FOR LAMBERT-EATON SYNDROME

被引：5
|
作者：
CHAPMAN, J
RABINOWITZ, R
KORCZYN, AD
MICHAELSON, DM
机构：
[1] TEL AVIV UNIV,SACKLER SCH MED,DEPT PHYSIOL & PHARMACOL,IL-69978 TEL AVIV,ISRAEL
[2] TEL AVIV UNIV,DR GEORGE S WISE CTR LIFE SCI,DEPT BIOCHEM,TEL AVIV,ISRAEL
来源：
MUSCLE & NERVE | 1990年 / 13卷 / 08期
关键词：
acetylcholine release; autoantibodies; electromyography; Lambert‐Eaton myasthenic syndrome; Torpedo;
D O I：
10.1002/mus.880130811
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Lambert‐Eaton myasthenic syndrome (LEMS) is an autoimmune disorder characterized by reduced acetylcholine release at the neuromuscular junction. We report a model of the disease developed by active immunization of rats with purely cholinergic nerve terminals (synaptosomes) isolated from the Torpedo electric organ. Electromyographic studies of neuromuscular transmission in these rats showed a weak initial response followed by a pronounced incremental response to paired supramaximal stimuli (8 msec apart). There was no such response in control rats. There was no evidence of a postsynaptic transmission deficit in the synaptosomes immunized rats. We conclude that immunizing rats with Torpedo cholinergic nerve terminals causes a specific presynaptic dysfunction and may serve as a model for the study of LEMS. Copyright © 1990 John Wiley & Sons, Inc.
引用
收藏
页码：726 / 733
页数：8
相关论文
共 50 条
  • [1] Lambert-Eaton Myasthenic Syndrome
    Kesner, Vita G.
    Oh, Shin J.
    Dimachkie, Mazen M.
    Barohn, Richard J.
    NEUROLOGIC CLINICS, 2018, 36 (02) : 379 - +
  • [2] Lambert-Eaton myasthenic syndrome
    Mareska, M
    Gutmann, L
    SEMINARS IN NEUROLOGY, 2004, 24 (02) : 149 - 153
  • [3] Lambert-Eaton myasthenic syndrome
    Hernandez, Micaela A.
    Kohler, Alejandro A.
    Marrodan, Mariano
    Lautre, Andrea
    Brand, Patricio
    Nogues, Martin
    Barroso, Fabio
    REVISTA DE NEUROLOGIA, 2021, 73 (03) : 96 - 100
  • [4] Lambert-Eaton myasthenic syndrome
    Seneviratne, U
    de Silva, R
    POSTGRADUATE MEDICAL JOURNAL, 1999, 75 (887) : 516 - 520
  • [5] Lambert-Eaton myasthenic syndrome - Diagnosis and treatment
    Sanders, DB
    MYASTHENIA GRAVIS AND RELATED DISORDERS: BIOCHEMICAL BASIS FOR DISEASE OF THE NEUROMUSCULAR JUNCTION, 2003, 998 : 500 - 508
  • [6] The Lambert-Eaton Myasthenic Syndrome: an Overview
    Kohler, Siegfried
    Meisel, Andreas
    AKTUELLE NEUROLOGIE, 2018, 45 (04) : 298 - 304
  • [7] Lambert-Eaton myasthenic syndrome in childhood
    Kostera-Pruszczyk, A.
    Ryniewicz, B.
    Rowinska-Marcinska, K.
    Dutkiewicz, M.
    Kaminska, A.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2009, 13 (02) : 194 - 196
  • [8] Treatment in Lambert-Eaton myasthenic syndrome
    Maddison, Paul
    MYASTHENIA GRAVIS AND RELATED DISORDERS II, 2012, 1275 : 78 - 84
  • [9] LAMBERT-EATON MYASTHENIC SYNDROME: UNDERSTANDING AND MANAGEMENT ADVANCES
    Antoniu, S.
    DRUGS OF THE FUTURE, 2013, 38 (07) : 513 - 519
  • [10] Amifampridines are the Most Effective Drugs for Treating Lambert-Eaton Myasthenic Syndrome With a Focus on Pediatric Lambert-Eaton Myasthenic Syndrome
    Oh, Shin J.
    JOURNAL OF CLINICAL NEUROLOGY, 2024, 20 (04): : 353 - 361
12345